Adrenergic β2 Receptors
The adrenergic β2 receptor (β2-adrenoceptor) is a member of the adrenergic receptor group of G-protein-coupled receptors that also includes α1A, α1B, α1D, α2A, α2B, α2C, β1 and β3. They are located primarily in the CNS, heart, kidney and muscle.
Adrenergic β2 Receptor Agonists |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 6219 | Arformoterol tartrate |
| Long-acting β2 agonist (LABA) | |
| 1448 | Formoterol hemifumarate |
| Potent and selective β2 agonist | |
| 1102 | Procaterol hydrochloride |
| Potent β2 agonist | |
| 0634 | Salbutamol hemisulfate |
| β2-adrenoceptor agonist | |
| 4712 | Salmeterol xinafoate |
| Long-acting β2 agonist; bronchodilator | |
Adrenergic β2 Receptor Inverse Agonists |
|
| Cat. No. | Product Name / Activity |
| 0821 | ICI 118,551 hydrochloride |
| Highly selective β2 inverse agonist | |
The adrenergic β2 receptor (β2-adrenoceptor) is a member of the adrenergic receptor group of G-protein-coupled receptors that also includes α1A, α1B, α1D, α2A, α2B, α2C, β1 and β3. They are located primarily in the CNS, heart, kidney and muscle where they are involved in smooth muscle relaxation (e.g. bronchodilation). The human adrenergic β2 receptor gene has been localized to chromosome 5 (5q31-q32)
External sources of pharmacological information for Adrenergic β2 Receptors :
Literature for Adrenergic β2 Receptors
Tocris offers the following scientific literature for Adrenergic β2 Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Written by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDF